Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx manufacturer vs compounder: Where to draw the lines

This article was originally published in Scrip

Executive Summary

"Do we need a bill or do we need an FDA that takes action?" Representative Tim Murphy (Republican-Pennsylvania) asked during a 16 July House hearing, spelling out, again, the issue his chamber has been grappling with for months – if not years – in the wake of more Americans being sickened and killed by tainted drugs compounded by pharmacies acting more like unregulated manufacturers.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC022115

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel